07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Ophthotech, Novartis deal

Ophthotech received a $50 million payment from Novartis under a May deal granting the pharma exclusive, ex-U.S. rights to develop and commercialize Fovista . The milestone was triggered by the enrollment of an undisclosed number...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Fovista: Phase IIa started

Ophthotech began an open-label, U.S. Phase IIa trial to evaluate Fovista in combination with anti-VEGF therapy in about 100 patients with wet AMD. Fovista is in Phase III testing to treat wet AMD, with top-line...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Ophthotech, Novartis deal

Ophthotech granted Novartis exclusive, ex-U.S. rights to develop and commercialize Fovista , which is in Phase III testing to treat wet age-related macular degeneration (AMD). Ophthotech, which retains sole commercialization rights in the U.S., will...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Ophthotech, Novo deal

Ophthotech received a second $41.7 million tranche from Novo under a 2013 deal granting Novo low- to mid-single digit royalties on sales of Fovista. The payment was triggered by Ophthotech reaching an initial enrollment milestone...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Fovista: Phase III started

Ophthotech began the first of 3 sham-controlled, international Phase III trials evaluating intravitreal injections of 1.5 mg Fovista in about 1,866 newly diagnosed wet AMD patients. According to in an S-1 filed by Ophthotech, the...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Ophthotech, Novo A/S deal

Ophthotech granted Novo undisclosed royalties on sales of age-related macular degeneration (AMD) drug Fovista in exchange for $125 million. Ophthotech received $41.7 million in the first tranche and is eligible for two equal, subsequent tranches...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Fovista: Phase IIb data

A double-blind, U.S. Phase IIb trial in 449 patients with neovascular wet AMD showed that once-monthly 1.5 mg/eye intravitreal Fovista plus Lucentis ranibizumab met the primary endpoint of improving mean visual acuity as measured by...
07:00 , May 3, 2012 |  BC Innovations  |  Tools & Techniques

Evolution not revolution

An international team has engineered enzymes capable of replicating nucleic acid polymers that are made of non-natural nucleotides. 1 Despite general media reports that the findings are a breakthrough on the way to artificial life,...
08:00 , Nov 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis (OA) Complement 5 (C5) Mouse and human studies suggest inhibiting C5 could help treat OA. In the synovial fluid...